Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients.

Abstract

Maxacalcitol (22-oxacalcitriol [OCT]) is a newly developed vitamin D analogue in Japan. OCT has shown less calcemic action and a strong suppressive effect on parathyroid hormone (PTH) in uremic rats and dogs. In uremic patients with secondary hyperparathyroidism, OCT dose-dependently suppressed PTH secretion and increased serum calcium levels. However, more… (More)

Topics

Cite this paper

@article{Akizawa2001ClinicalEO, title={Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients.}, author={Tadao Akizawa and M. Suzuki and Tohoru Akiba and Yoshiki Nishizawa and Kohei Kurokawa}, journal={American journal of kidney diseases : the official journal of the National Kidney Foundation}, year={2001}, volume={38 4 Suppl 1}, pages={S147-51} }